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ABSTRACT
Retroviruses require both spliced and unspliced
RNAs for replication. Accumulation of Rous
Sarcoma virus (RSV) unspliced RNA depends upon
the negative regulator of splicing (NRS). Its 50-part is
considered as an ESE binding SR proteins. Its
30-part contains a decoy 50-splice site (ss), which
inhibits splicing at the bona fide 50-ss. Only the 3D
structure of a small NRS fragment had been experi-
mentally studied. Here, by chemical and enzymatic
probing, we determine the 2D structure of the entire
RSV NRS. Structural analysis of other avian NRSs
and comparison with all sequenced avian NRSs
is in favour of a phylogenetic conservation of the
NRS 2D structure. By combination of approaches:
(i) in vitro and in cellulo splicing assays, (ii) footprint-
ing assays and (iii) purification and analysis of
reconstituted RNP complex, we define a small NRS
element retaining splicing inhibitory property. We
also demonstrate the capability of the SR protein
9G8 to increase NRS activity in vitro and in cellulo.
Altogether these data bring new insights on how
NRS fine tune splicing activity.
INTRODUCTION
For all retroviruses, alternative splicing plays a key role in
the modulation of gene expression. After integration
within the host genome, the proviral genome is transcribed
as a primary transcript by RNA polymerase II. A large
number of the transcribed molecules remain unspliced.
They are needed to serve as genomes for new virions
and as messenger RNAs for translation of the Gag–Pol
protein precursor. The remaining part of the primary tran-
script undergoes alternative splicing in the nucleus to
generate mRNAs for production of other retroviral
proteins. Rous Sarcoma virus (RSV), which was the ﬁrst
discovered replication competent oncogenic retrovirus,
exempliﬁed this situation (1). This simple avian retrovirus
belongs to the avian sarcoma/leucosis virus (ASLV)
family. It contains the gag, pol and env genes common
to all retroviruses and codes the oncogenic protein v-Src.
ASLV viruses deserve interest because of the damage they
generate in poultry breeding. In addition, RSV is an inter-
esting, already well-studied model, to investigate mechan-
isms involved in the regulation of retroviral alternative
splicing (2). Its RNA contains a single 50-splice site (ss)
(position 398 as referred to the transcription start site) and
two 30-ss in competition one with the other, the env and src
30-ss (positions 5078 and 7054, respectively). Coupling of
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of the env and src mRNAs, respectively.
The low level of RSV RNA splicing (20–30%) is due to
the presence of suboptimal splicing sites and to the
presence of strong splicing inhibitory elements. The
branch point sequence of the env 30-ss is not canonical
and the polypyrimidine tract of src 30-ss is suboptimal
(3–6). Splicing at the src 30-ss is speciﬁcally down regulated
by an upstream sequence named SSS for suppressor of src
splicing (SSS) (7). SSS seems to bind an unknown factor
speciﬁc to chicken cells and its mechanism of action is not
elucidated. A dr1 direct repeat ﬂanks the src gene. It was
ﬁrst identiﬁed as a constitutive transport element (CTE)
promoting the accumulation of unspliced viral RNA into
the cytoplasm (8,9). This element may in addition contain
a second silencing element acting speciﬁcally on the
src 30-ss (10,11). A third negative cis-splicing regulatory
sequence, called the negative regulator of splicing
(NRS), prevents splicing at both 30-ss (12–15). NRS
(positions 703–930) is located in the gag gene  300nt
downstream from the 50-ss.
NRS was found to inhibit splicing of a heterologous
myc intron as well in vitro as in cellulo. Deletion of an
internal 76-nt long segment (nucleotides 799–874) (NRS
76) had a limited effect on NRS activity (13). Thus, NRS
76 was deﬁned as the minimal sequence required for
splicing inhibition activity. Two segments of the NRS
were described as having an important role for splicing
inhibition: the NRS 50-part (positions 700–800, NRS-50)
was found to have splicing enhancer activity in an heter-
ologous context, the NRS 30-terminal part (positions
801–930, NRS-30) contains two overlapping 50-ss se-
quences. One is capable of binding U1 snRNA (major
site), the other one binds the U11 snRNP (minor site)
(16–18). U1 snRNP binding does not induce splicing
and is required for the inhibition activity, suggesting
that the degenerated major 50-ss (ﬁve out of eight
matches ﬁt to the 50-ss consensus) is a decoy 50-ss (17).
Unlike U1 snRNP, U11 snRNP binding to the minor
50-ss is dispensable for splicing inhibition and is just
expected to have a moderate negative effect on U1
snRNP binding to the major site (17,18). NRS-50-had
been shown to bind SR proteins and hnRNP H (19–21).
Binding of SR proteins to the NRS-50 segment was
proposed to enhance U1, but not U11 snRNP recruitment
(18). The NRS appears to function as a non-productive
decoy 50-ss, which competes with the authentic viral 50-ss,
and forms abortive spliceosomal complexes when coupled
to one of the two 30-ss. In vitro analysis demonstrated
that human U5-220kD protein (hPrp8) does not cross
link to the NRS pseudo 50-ss, highlighting the fact that
the abortive complex cannot switch into a catalytic
complex (22).
A computer assisted 2D structure model of the NRS
element was proposed long time ago (13). In this model,
the NRS-50 and NRS-30 regions are paired together. Our
earlier chemical and enzymatic probing of part of the NRS
structure in collaboration with the Beemon group showed
that the NRS-30 region, encompassing nucleotides from
positions G910 to U926, forms an individual stem–loop
structure and this was the basis for an NMR-3D structure
analysis of this NRS fragment (23). Formation of the
identiﬁed stem–loop structure is incompatible with the
proposed 2D structure of entire NRS. An experimental
analysis of the 2D structure of the entire NRS element
was therefore needed to get a clear answer on how NRS
folds. As determination of RNA 3D structure by NMR
can only be performed on short RNAs, only the RNA
probing method based on utilization of chemical and
enzymatic probes was adapted to this purpose. It should
be pointed out that RNA 2D structure was already shown
to play an important role in pre-mRNA splicing regula-
tion (24–26). Therefore, determination of the NRS struc-
ture was expected to bring some insight on how NRS
inhibits splicing.
In this article, we performed an experimental analysis of
the entire RSV and ALV LR9 NRSs (27,28) 2D struc-
tures. The data provide evidence for a cruciform structure
different from the previously proposed computer-based
2D structure. In the new cruciform structure, NRS-30
forms an individual stem–loop structure, which is in ac-
cordance with previous NMR data (23). The NRS-50
segment that binds ASF/SF2 also forms a stem–loop
structure. Based on these data and in order to test for
phylogenetic conservation of the NRS 2D structure, we
undertook a comparative analysis of the possible 2D
structures of avian retrovirus NRSs using available
avian retrovirus nucleotide sequences. In parallel, we
tested the NRS activity of truncated forms of the RSV
NRS by in vitro splicing assays using a hybrid construct
derived from HIV-1. By this approach, we identiﬁed a
small discontinuous 114-nt element as the minimum
element required for splicing inhibition. Then, we used a
new afﬁnity chromatography procedure (29) to deﬁne
which of the produced truncated RSV NRSs can recruit
the SR proteins ASF/SF2, SC35 and 9G8. Our ﬁnding of
a strong binding of the SR protein 9G8 on WT and some
of the truncated NRSs stimulated us to test the activation
role of this SR protein on RSV NRS activity. By in vitro
and in cellulo assays, we demonstrated a strong stimula-
tory effect of protein 9G8 on RSV NRS activity and we
identiﬁed its binding site on RSV NRS by footprinting
assays.
MATERIALS AND METHODS
DNA constructs
The 2D structure of NRS WT, NRS 76, LR9 and LR9
RNAs was analysed on transcripts produced from
PCR products. PCR products were ampliﬁed from the
earlier described pRSVNeo-Int, p76Neo-Int, pLR9 and
pLR9 plasmids (13,28). Plasmids pRSVNeo-Int,
p76Neo-Int contain DNA sequences of the WT and
76 RSV NRSs from strain Prague C (PrC) (13), respect-
ively. The sense primer (O-2954, Supplementary Table S1)
contained a T7 RNA polymerase promoter and the anti-
sense primer (O-2955, Supplementary Table S1) contained
the unrelated AAATT sequence at its 50-end (Figure 1A).
To get constructs containing WT and 76 NRS coding
sequences under the control of a T7 RNA polymerase
promoter, which are fused to a DNA sequence coding
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Figure 1. (A) Schematic representation of the RSV Prague C (PrC) genome and of the NRS RNAs used for secondary structure analyses. The
architecture of the RSV PrC genome is shown on top of the Figure. The 50-ss and 30-ss are indicated and boxes represent the open reading frames.
The grey box depicts the NRS element (nucleotides 703–930) located in the gag gene used for secondary structure experiments. Viral sequences
belonging to the RSV segments located upstream and downstream from NRSs are in white. The non-viral AAAUU sequence at the 30-end of the
transcripts is shown. Delimitations of NRS are indicated according to NRS nucleotide numbering (48). (B and C) Primer extension analyses of
enzymatic cleavages and chemical modiﬁcations of NRS WT. (B) Primer extension analyses of enzymatic cleavages in NRS WT (position 691– 951)
(B1–B3), (C) primer extension analyses of chemical modiﬁcations in NRS WT (position 710 to 890) (C1 and C2). T1, T2, V1, D and Ke above the
lanes indicate T1, T2, V1 RNase digestions and DMS or Kethoxal modiﬁcations, respectively. Conditions for digestions, modiﬁcations and reverse
transcription are given in ‘Materials and Methods’ section. Lanes c correspond to control experiments with untreated RNA; lanes U, G, C and A
correspond to the sequencing ladder. Primers used for reverse transcription are indicated below each autoradiogram (see Supplementary Table S1 for
their nucleotide sequences). Nucleotide numbering according to (48) is indicated on the left side of the autoradiograms. Positions of the stem–loop
structures (SLS1, SLS2, SLS3 and SLS4) and the helices (H1 and H2) are shown on the right side of the autoradiograms.
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MS2 DNA sequences were excised from plasmid
pADML-M3 (30) by BamHI–HindIII digestions and
were subcloned into plasmid pUC18 (pMS2 plasmid).
To obtain the control pT7MS2 plasmid, a T7 promoter
was generated by annealing primers O-4672 and O-4673
and the resulting DNA was inserted between the BamHI
and SacI sites located upstream of the MS2 DNA in
plasmid pMS2. To get pNRS-MS2 and pNRS 76-MS2
plasmids, the NRS WT and NRS 76 DNA fragments
were PCR ampliﬁed with O-4666 (containing a T7
promoter sequence) and O-4667 and inserted into a
BamHI/SacI digested pMS2 plasmid. Other NRS variant
DNAs, NRS 22, NRS 24, NRS 26 and NRS 28 were
obtained by PCR mutagenesis using the primers pairs
O-5422/O-5423, O-5424/O-5425, O-5426/O-5427 and
O-5428/O-5429, respectively (Supplementary Table S1).
For in vitro splicing assays, plasmid pC2-NRS and its
derivatives were produced by insertion of the NRS DNA
sequences in the sense (pC2-NRS and derivatives) or anti-
sense orientations (pC2-NRS Inv) into the intron of the
earlier described C2 HIV construct built with HIV-1 BRU
cDNA (31). These constructions were made in two steps
using PCR primers described in Supplementary Table S1.
First, the HIV sequence from position 4871 to 5053 was
PCR ampliﬁed and cloned between the PstI and EcoRI
sites of plasmid pUC18. Second, a DNA fragment con-
taining a T7 RNA polymerase promoter followed by the
HIV sequence including exon 1 (nucleotides 1–289) and
the intron from position 290 to 340 and a second fragment
corresponding to RSV NRS WT were PCR ampliﬁed,
ligated together using BglII sites introduced at their
extremities and cloned into the HindIII and PstI sites of
plasmid pC2 to obtain pC2-NRS. The same strategy was
used to insert the NRS sequence in the reverse orientation
(NRS Inv) and the NRS 76 sequence. Other NRS
variant DNAs, NRS 22, NRS 24, NRS 26 and NRS 28
were obtained by PCR mutagenesis as described above.
To produce plasmids used for transfection assays, frag-
ments from pC2, pC2-NRS WT and pC2-NRS Inv con-
structs were ampliﬁed using O-5824 and O-5825 and
cloned between the NcoI and XbaI sites of plasmid
pGL3c (Promega), so that, C2-NRS DNA sequences
replaced the luciferase gene and were under the control
of the SV40 promoter (pGL3-C2, pGL3-C2 NRS WT
and pGL3-C2 NRS Inv, respectively). The SV40 poly(A)
signal sequence was located at the other extremity.
Plasmid pXJ42-9G8 (32) was used for overexpression of
the 9G8 SR protein. The empty pXJ42 plasmid was used
in control experiments. Plasmid phRGB (Promega) was
used to verify the efﬁciency of transfection during
overexpression experiments. The pBluescript SK-II
(Stratagene) was used in order to reach a ﬁnal amount
of 2 and 4mg of plasmid during the overexpression and
siRNA experiments, respectively.
RNA transcription
For RNA secondary structure analysis and RNP puriﬁca-
tion using MS2-RNAs, unlabelled RNAs were transcribed
using 1.7–3pmols of PCR products and T7 RNA
polymerase in conditions described earlier (33).
Transcripts were puriﬁed by electrophoresis on 5% poly-
acrylamide gel as described earlier (33). For in vitro
splicing assays, 5mg of plasmid were linearized by EcoRI
and used as the template for the synthesis of unlabelled
capped RNAs as described earlier, except that [a-
32P] UTP
was omitted (31). After digestion of the DNA matrix with
5ml of TURBO DNase (Ambion), RNAs were puriﬁed
using the GenElute kit (Sigma-Aldrich) according to
manufacturer’s recomendations.
RNA secondary structure analysis
RNA secondary structure analyses were performed on
100ng of RNA transcript, in the presence of 3.125mM
MgCl2 in buffer D (73mM KCl, 0.15mM EDTA,
0.35mM DTT, 0.18mM PMSF, 15% glycerol, 15mM
HEPES–KOH pH 7.9) and in the presence of 5mgo f
yeast tRNA mixture. RNA was pre-incubated for 5min
at 65 Ci n1 5ml of buffer D and after slow cooling to 30 C,
0.5U of RNase T1 (Roche), 0.25U of RNase T2
(Invitrogen) or 5 10
 5U of RNase V1 (Kemotex) were
added and incubation was continued for 10min at 30 C.
RNase V1 hydrolyses were stopped by addition of 1mlo f
100mM EDTA and 20mg of yeast tRNA. RNase T1 and
T2 hydrolyses were stopped by addition of 20mgo f
yeast tRNA, followed by phenol extraction and ethanol
precipitation. Kethoxal and DMS modiﬁcations were per-
formed as described earlier (34). Positions of enzymatic
and chemical cleavages were identiﬁed by primer exten-
sion analyses using Avian Myeloblastosis virus reverse
transcriptase (Q Biogene) and the 50-end labelled primers
described in Supplementary Table S1. Primer 50-end-
labelling, annealing and extensions were performed as
described earlier (34). The sequencing ladder was
obtained as usual, using the RNA sequencing method
(34) with the same primer as for identiﬁcation of
cleavage and modiﬁcation positions.
RNA secondary structure prediction and phylogenetic
analysis
Predictions of secondary structure were made with the
Mfold software version 3.2 (available at http://mfold
.bioinfo.rpi.edu/cgi-bin/rna-form1.cgi) (35,36). The
Mfold calculated thermodynamic values correspond to
RNA in 1M NaCl at 37 C. Results of experimental
analyses were introduced in the computer search, in order
to deﬁne the most stable secondary structure which had the
best ﬁt with the experimental data.
The GenBank accession number of RSV and related
ASLV sequences used in the comparative secondary struc-
ture analysis are: L29198 (Schmidt Ruppin A), AF052428
(Schmidt Ruppin B), DQ365814 [ALV MQNCSU (A)],
AY027920 (ALV ADOL-7501), AB303223 (ALV Stain
Tym_S90), AF033810 (Fujinami Sarcoma Virus),
V01170 (Y53 Sarcoma Virus).
Footprinting assays on complexes formed with
recombinant 9G8 protein
To form 9G8-NRS RNP complexes, 100ng of cold NRS
WT RNA transcript (1.17pmol) and 5mg of yeast tRNA
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MgCl2. NRS WT RNA transcript was denatured for
5min at 65 C and after slow cooling at 30 C, recombinant
protein was added. Then, 0.7 or 1.5mg (28.5 and 57pmol,
respectively) of puriﬁed recombinant 9G8 protein ex-
pressed in baculovirus and puriﬁed as described earlier
(37) were added. Complexes were formed by incubation
for 10min at 30 C and then, 0.75U of T1 RNase was
added for 10min at 30 C. The reaction was stopped by
addition of 20mg of yeast tRNA mixture and by rapid
cooling to 0 C, immediately followed by phenol extrac-
tion. As a control, enzymatic digestion was performed
with the same amount of NRS WT RNA transcript and
yeast tRNA incubated in the same conditions except
that 9G8 protein was missing. Positions of enzymatic
cleavages were identiﬁed by extension of 50-end-labelled
primers (Supplementary Table S1), in conditions described
earlier (34). The sequencing ladder was obtained as usual,
using the RNA sequencing method (34) with the same
primer as for identiﬁcation of cleavage and modiﬁcation
positions. Experiments were all repeated several times
using different batches of RNA transcripts.
MS2 afﬁnity chromatography
The procedure used was an adaptation of the one
described earlier (29). MS2-tagged puriﬁed WT or
variant NRS RNAs (250pmol) were denatured, renatured
and incubated with a 5-fold molar excess of puriﬁed MS2-
MBP fusion protein at 4 C for 30min. This protein was
prepared as described earlier (38). The RNA–MS2–MBP
complexes formed were incubated for 30min at 4 C, with
4.3mg of HeLa nuclear extract in a 1.1ml of buffer D
containing 60mg of yeast tRNA. The HeLa nuclear
extract was purchased from CILBiotech. Then, 100mlo f
amylose beads (GE Healthcare) equilibrated in buffer D
were incubated with the complexes for 1h at 4 C under
constant agitation. Three successive washes with buffer D
were performed, and RNP complexes were eluted by in-
cubation with 100ml of buffer D containing 15mM
maltose (30min at 4 C). About 10% of the proteins con-
tained in the eluted RNP complexes were fractionated by
10% SDS–PAGE for western blot analysis. Another 10%
of the eluted material was phenol extracted and RNAs
were fractionated on a 10% denaturing polyacrylamide
gel for northern blot analysis. Finally, for WT NRS-
MS2 and control MS2–RNP complexes, the remaining
part of the eluate was fractionated by SDS–PAGE and
the gel was systematically sliced. Then, proteins extracted
from the bands were analysed by nano-liquid chromatog-
raphy–mass spectrometry experiments, using a CapLC ca-
pillary liquid chromatography system (Waters, Milford,
MA, USA) coupled to a hybrid quadrupole time-of-ﬂight
mass spectrometer (Q-TOF II, Waters) according to
standard protocols (39).
In vitro splicing assays
Twenty fmol of puriﬁed pre-mRNA that contained the
WT NRS sequence, its reverse sequence or variant NRS
sequences inserted in the C2 HIV-1 pre-mRNA were
incubated for 2h at 30 Ci na2 2 ml standard reaction
containing 8ml of HeLa cell nuclear extract (31). To
study the inﬂuence of protein 9G8 on NRS activity,
splicing reactions were performed with a 1:1 mixture of
HeLa cell cytoplasmic extract and HeLa cell nuclear
extract and 180 or 270ng of puriﬁed recombinant
human 9G8 protein (produced in baculovirus) or 500ng
of commercial puriﬁed BSA used as a control. Splicing
reactions were stopped by addition of 20mgo f
Proteinase K, followed by phenol/chloroform extraction.
RNAs were ethanol precipitated and dissolved in 20mlo f
bi-distilled H2O. Reverse transcriptions were performed
by addition of 2ml of this solution in 20mlo f
1 MMLV buffer (Promega) containing 5pmol of
O-5825 primer, 1mM of each dNTP, 1ml of RNAguard
(GE Healthcare) and 200U of MMLV reverse transcript-
ase (Promega). Incubation was for 1h at 37 C. In order to
detect spliced RNAs, PCR ampliﬁcations were performed
with the O-6246/O-6519 primer pair. To detect both
spliced and unspliced RNAs, the PCR ampliﬁcation was
performed with the O-6519/O-6187 primer pair. PCR
reactions were performed in semi-quantitative conditions
using 50mlo f1 GoTaq buffer containing 1ml of reverse
transcriptase products, 200mM of each dNTP, 1mMo f
each primers and 1.25U of GoTaq polymerase
(Promega). The following protocol was used: initial
denaturation for 5min at 94 C, followed by 30 cycles of
ampliﬁcation for analysis of spliced plus unspliced RNAs
(Sp+UnSp) or 35 cycles of ampliﬁcation for analysis of
spliced RNAs (Sp). Each cycle included incubations for
30s at 94 C, 45s at 46 C and 45s at 72 C. After agarose
gel electrophoresis, ethidium bromide ﬂuorescence of RT–
PCR products was quantiﬁed using a digital ccd camera
(GeneGenius, SynGene) and the SynGene GeneTools
version 3.08 software. Each in vitro splicing experiment
was repeated three times using different batches of
RNAs and for each assay, RT–PCR ampliﬁcations were
performed in triplicate. The mean values of the three RT–
PCR experiments and their standard deviations were es-
tablished. This allowed us to estimate the mean values of
splicing efﬁciencies and their standard deviations.
Student’s t-paired test was used for statistical analysis.
In cellulo splicing assays
HeLa cells were grown in Dulbecco modiﬁed Eagle’s
medium (DMEM Sigma-Aldrich) supplemented with
10% of fetal calf serum and 2mM glutamine. About
24h before transfection, cells were seeded in six well
plates at a density of 200000 cells per well. To test for
the effect of 9G8 expression, cells were cotransfected
with 0.5mg of plasmid pGL3-C2, pGL3-C2 NRS WT or
pGL3-C2 NRS Inv expressing the hybrid pre-mRNAs,
0.5mg of pXJ42-9G8 expressing 9G8 and 0.9mgo f
empty pXJ42 plasmid, together with 0.1mg of phRGB
plasmid encoding the renilla luciferase, this plasmid was
used to verify transfection efﬁciency. In control experi-
ments the pXJ42-9G8 plasmid was omitted and 1.4mgo f
empty pXJ42 plasmid was used in order to maintain the
same total amount of plasmid. Transfections were per-
formed with the JetPEI (Polyplus-transfection kit) in a
3392 Nucleic Acids Research, 2011,Vol.39, No. 8DNA/JetPEI ratio of 1:2, according to manufacturer’s
recommendations.
For siRNA experiments, HeLa cells were grown in
OptiMEM medium (Invitrogen), supplemented with 5%
fetal calf serum, in the absence of antibiotics. As above,
24h before transfection, cells were seeded in six well plates
at a density of 200000 cells per well. Cells were transfected
using lipofectamine 2000 (Invitrogen) according to the
manufacturer’s recommendations. Two successive trans-
fections of 100nM of siRNA directed either against
9G8 mRNA [si9G8, (40)] or against the Renilla luciferase
transcript of plasmid phRGB [siLuc, (41)] were carried
out at 24h interval. Cells were transfected 24h after
the second siRNA treatment with the following plasmid
mixture: 0.5mg of either pGL3-C2, pGL3-NRS WT
or pGL3-C2 NRS Inv and 3.5mg of pBSK plasmid
per well.
To estimate the in cellulo splicing efﬁciencies, total
cellular RNA was extracted with the GenElute kit
(Sigma-Aldrich), 48h after the unique transfection step
for overexpression experiments and 24h after the third
transfection step for siRNA experiments. Then, 4mgo f
total cellular RNA were treated with 4U of TURBO
DNase (Ambion) in a 20ml of TURBO DNase buffer
1 for 30min at 37 C. The reaction was stopped by
adding 20ml of 30mM EDTA and heating at 75 C for
15min. Finally, 1mg of DNase treated RNA was subjected
to reverse transcription, using 0.5pmol of oligo(dT)18 as
primer and PCR ampliﬁcation and quantiﬁcation were
performed as described above. Two independent experi-
ments were performed for the 9G8 overexpression and
siRNA experiments, respectively. In each experiment,
total cellular proteins were extracted and analysed by
SDS–PAGE followed by western blot analysis, using
antibodies speciﬁc for 9G8 and b-tubulin
(Sigma-Aldrich) as described earlier (41).
RESULTS
Experimental analysis of the RSV NRS 2D structure
To analyse experimentally the 2D structure of the entire
RSV NRS in solution, we used RNases T1 and T2 in
conditions such that they only cleaved single-stranded
segments and V1 RNase which cleaves speciﬁcally
double-stranded and stacked RNA regions. Inspection
of the NRS bordering sequences in ASLV retroviruses
revealed the conservation of a C-rich segment 50 to NRS
and of a G-rich segment 30 to NRS. These two segments
showed conserved complementarity in the ASLV family.
We hypothesized that they may form a helix closing the
NRS. Therefore, our structural analyses were performed
on an in vitro transcript produced by T7 RNA polymerase
that encompassed the RSV RNA segment from position
691 to 951 (NRS encompasses nucleotides 703–930)
(Figure 1A). The cleaved NRS residues were identiﬁed
by primer extension analyses. Efﬁcient binding of RT
primers requires their base pairing with single-stranded
residues. Hence, an AAAUU sequence, which was not
expected to interfere with the helix predicted to be
formed by segments 691–700 and 940–947, was added at
the 30-end of the transcript (Figure 1A). The RT primer
(O-2955) complementary to this additional sequence and
segment 939–951 (Supplementary Table S1) was efﬁcient
to identify cleavages located between positions 901 and
936. We deﬁned two other primers (O-1619 and
O-1617), which allowed us to identify RNase cleavage
positions in the entire NRS region (Supplementary
Table S1). The 2D structure probing experiments were
performed after RNA refolding in conditions described
in ‘Materials and Methods’ section. Experiments were
repeated several times and reproducible results were
obtained. Examples of primer extension analyses are
shown in Figure 1B (B1–B3). Enzymatic probing experi-
ments were completed by chemical probing experiments.
We used DMS, which methylates single-stranded adeno-
sines at position N-1 and single-stranded cytosines at pos-
ition N-3, and kethoxal that modiﬁes unpaired guanine
residues at position N-3. Location of modiﬁcations was
also achieved by primer extension analyses, representative
examples are shown in Figure 1C (C1 and C2).
Computer assisted determination of the RSV NRS
structure
The previously proposed computer predicted structure
for RSV NRS WT (13) could not explain the results
of our chemical and enzymatic probing experiments
(Figure 2A). To search for the most stable 2D structure
in agreement with our experimental data, we used the
Mfold software (35,36) and introduced our data as con-
straints. The structure identiﬁed (Figure 2B) has a very
low free energy ( 83.5kcal/mol). In agreement with our
previous probing data, which has served as the basis
for NMR analysis of the NRS-30 structure (23), segment
907–929 containing both the U1 and U11 binding sites,
forms an individual stem–loop structure (SLS4). In the
established structure, segment 717–747, which was previ-
ously found to bind the ASF/SF2 SR protein (19), also
folds into an individual stem–loop structure (SLS1).
As expected, the 30- and 50-termini of the NRS form
an irregular helix (H1) that is extended by the complemen-
tary sequences bordering the NRS. The segment from
position 750 to 778, which was previously proposed to
bind several SR proteins and hnRNP H, forms a very
long irregular helix (H2) by interaction with segment
877–902. The sequence from position 781 to 850, which
is largely deleted in the functional NRS 76 truncated
element, is involved in formation of a long irregular
SLS2 stem–loop structure, and fragment 854 to 868
which is also deleted in NRS 76, forms a small stem–
loop structure (SLS3).
The main structural features of NRS are conserved in the
NRS "76 variant
As the variant NRS 76 is functional, we hypothesized
that its 2D structure should not be drastically modiﬁed.
To verify this hypothesis, we probed its structure experi-
mentally. The NRS 76 transcript contained the same
additional sequences at the 50- and 30-extremities as the
full length NRS transcript used above, and was analysed
as the full length NRS. The data obtained are in perfect
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loops SLS1 and SLS4 in NRS 76 (Figure 2C and
Supplementary Figure S1). The parts of the SLS2 and
SLS3 stem–loops, which are remaining in NRS 76,
form two base pairs extending helix H2 and a large
terminal loop. Therefore, the 2D structure elements
formed by sequences which are important for binding of
U1 snRNA, U11 snRNA (SLS4), SR and hnRNP proteins
(SLS1, H1 and H2, respectively) are conserved in the NRS
76.
NRSs from viruses of the ASLV family can fold
according to the structure established for RSV NRS
LR9 is an RSV-related recombinant ALV virus which
contains the gag, pol and env genes derived from the
UR2-associated virus (UR2AV) and the LTR of
ring-necked pheasant virus (RPV) (27). Its NRS element
is highly similar to RSV NRS (10 base substitutions) and
shows similar efﬁciency in an heterologous context (27).
To test whether the presence of these 10 base substitutions
are compatible with the 2D structure established for the
RSV NRS, we produced an LR9 NRS transcript homolo-
gous to that used for RSV NRS and probed its structure
with T1, T2 and V1 RNases. As shown in Supplementary
Figure S2, base substitutions are either located in single
strands, or reinforce the stability of helix H2. Therefore,
the possibility to form the structure is preserved. Note that
when repeating the same experiment on the defective LR9
NRS deletion mutant (LR9), which is missing the
segment 735 to 776 (27), we observed strong 2D structure
alterations (Supplementary Figure S3): the SLS1 structure
disappeared and, helix H2 and SLS2 were remodelled.
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C
Figure 2. Schematic representation of the experimental data on the previously proposed structure for RSV NRS WT (13) in (A), and on the
secondary structure models that we established for RSV WT and RSV 76 NRSs (B and C, respectively). Cleavages by enzymes and modiﬁcations
by chemical reagents are depicted as shown in the inset (modiﬁed residues are circled, phosphodiester bonds cleavages by T1, T2 or V1 RNases are
indicated by arrows surmounted by lozenges, circles or squares, respectively). The intensities of cleavages and modiﬁcations are indicated by colors
(red, orange and green for strong, medium and low, respectively). Positions of nucleotides are according to (48). Stem–loop structures (SLS) and
helices (H) are numbered. The free energies of the proposed structures as calculated by the Mfold software (37 C, in 1M NaCl) (35,36) are given
below each structure. The hybridisation sites used for primer extensions are indicated by blue arrows. The underlined sequences at the 30-end of the
RNAs correspond to the added unrelated nucleotides.
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defective NRS are profoundly altered.
Then, for a larger investigation on the possible phylo-
genetic conservation of the NRS 2D structure, we took
advantage of the available sequences for several ASLVs
genomic RNAs (42). As shown in the Supplementary
Figure S4, A–G, the nucleotide sequences involved in
formation of helix H1, SLS1 and SLS4 stems are highly
conserved. Only one half of helix 2 has a conserved
sequence. The various base substitutions, insertions or
deletions in the viruses that we compared have no
expected detrimental effect on the RNA 2D structure,
which is in favour of a phylogenetic conservation of the
NRS 2D structure.
A minimal NRS element including helix H1 and
stem–loops SLS1 and SLS4 is active in vitro
Then, based on the established structure, we generated
internal truncation in the NRS in order to deﬁne the
minimal NRS sequence required for NRS activity. To
this end, we used a heterologous construct derived
from the HIV-1 C2 construct (Figure 3A1) (31) which
produces a pre-mRNA containing a short intron
bordered by the HIV-1 strong D1 50-ss and the A2 30-ss.
Site A2 has a limited efﬁciency due to the presence of
the ESSV splicing silencer that binds hnRNP A1 (43),
and up to now, only an activation by the SR protein
ASF/SF2 was detected at this site (44). Therefore, we
A
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Figure 3. Comparison of splicing inhibition properties of NRS WT and 76, 22, 24, 26 and 28 NRS variants in the C2 pre-mRNA context.
(A) Schematic representation of the HIV C2 pre-mRNA (A1) (31) and C2-NRS heterologous pre-mRNAs (A2). Black boxes and thin lines represent
exons and intron, respectively. Numbering of C2 RNA is according to (49). End-joining of the two HIV-1 sequences in the C2 intron is depicted by
an arrow. The D1 50-ss and A2 HIV-1 30-ss as well as the ESSV regulatory element are shown (43). Heterologous C2-NRS constructs, created by
insertion of the WT and variant 76, 22, 24, 26 and 28 NRSs in the intron, are schematically represented below. Segments deleted in the variant
NRS elements are in grey. The RT (in grey), and PCR (in black) primers used for evaluation of the yields of C2 and C2-NRS pre-mRNAs splicing
efﬁciencies are represented by arrows above the C2-NRS construct. Yields of spliced RNAs (Sp) and of spliced plus unspliced products (Sp+UnSp)
were analysed by PCR ampliﬁcations using the pairs of primers marked by Sp and Sp+UnSp, respectively. (B) RT–PCR analysis of in vitro splicing
products of the C2 and heterologous C2-NRS pre-mRNAs. In vitro splicing assays were performed as described in ‘Materials and Methods’ section.
Experiments were repeated three times using different batches of RNA (Supplementary Figure S5A). The relative splicing efﬁciencies of the various
constructs were estimated by semi-quantitative RT-PCR performed in triplicate (Supplementary Figure S5A). A representative example of cDNA
fractionation obtained for each of the tested pre-mRNAs is shown (B1). Identities of RT–PCR products spliced (Sp) or spliced plus unspliced
(Sp+UnSp) products are indicated. The identity of the pre-mRNA used in the assay is given above the lane. The Sp/Sp+UnSp pre-mRNA ratio
obtained for the C2-NRS Inv construct was taken as the reference (100%). The Sp/Sp+UnSp ratios established for the other constructs are given as a
percentage of this reference. The mean values of the Sp/Sp+UnSp percentages determined for three independent splicing reaction and their standard
deviations are given (B2). *P<0.05, **P<0.01, NS: not signiﬁcant.
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model to compare activities of WT and variant NRSs.
The NRS WT coding sequence was inserted in the
middle of the C2 intron (Figure 3A2). In these conditions,
the NRS pseudo 50-ss was located 278nt downstream
from the HIV-1 D1 50-ss. This distance was selected as
it was previously shown to be optimal for NRS activity
(13). As in vitro splicing efﬁciency is dependent on the
length of the intron to be spliced, we compared the
splicing efﬁciency of C2-NRS WT RNA to a control
C2 RNA containing the NRS sequence in the reverse
orientation (C2-NRS Inv RNA). Transcripts were
spliced in a Hela cell nuclear extract, as described in
‘Materials and Methods’ section. The ratio of spliced
(Sp) versus unspliced plus spliced (Sp+UnSp) products
was quantiﬁed by RT–PCR as described in ‘Materials
and Methods’ section (Figure 3A2, and Supplementary
Table S1). For each transcript, splicing assays were per-
formed in triplicate and highly reproducible results were
obtained as evidenced by data in the Supplementary
Figure S5A. As expected, insertion of a non-related
266-nt long sequence in C2 RNA decreased the in vitro
splicing efﬁciency by  40% (C2-NRS Inv RNA compared
with C2 RNA). However, the decrease observed for
the C2-NRS WT RNA was reproducibly more drastic
(80%), demonstrating NRS activity in the C2 context.
We thus considered that this model is valid and could be
used to test the effects of deletions in NRS on splicing
efﬁciency.
As a positive control, we used the functional NRS 76
mutant and we produced four other variants (Figure 3A2).
In variant 28 both stem–loops SLS2 and SLS3, as well
as a very small portion of helix H2, were deleted. In
variant 22, helix H2 and stem–loops SLS2 and SLS3
were deleted. In this variant, only helix H1 and the
stem–loops SLS1 and SLS4 are present and they are
joined by a 7-nt long single-stranded segment. Stem–
loop SLS4 was deleted in variant 24 and SLS1 was
absent in variant 26. As expected NRS 76 was as efﬁ-
cient in splicing inhibition as the NRS WT (Figure 3B1
lane 4 and B2). Interestingly, NRS 28, which is smaller
than NRS 76, had a splicing inhibitory property
superior to that of NRS 76 (Figure 3B1 lane 8 and
B2). No splicing inhibition was detected for NRS 24,
which conﬁrmed the requirement of the U1 snRNA
binding site for NRS activity (Figure 3B1 lane 6 and
B2). The same absence of inhibition was observed for
NRS 26, showing that deletion of stem–loop SLS1
(position 717–747) has the same negative effect on
NRS activity as deletion of stem–loop SLS4 (Figure 3B1
lane 7 and B2). Accordingly, previous data (20) showed a
strong loss of NRS activity with a deletion which included
part of the SLS1 sequence (deletion from position 720 to
744). Importantly, NRS 22, which only contained stem–
loops SLS1 and SLS4 and helix H1, had a negative effect
on splicing similar to that of NRS 76. Therefore,
our data reveal that a very small truncated NRS variant
containing only stem–loop structures SLS1 and SLS4
and helices H1 and H2 is sufﬁcient to inhibit splicing
in vitro.
Sequences corresponding to SLS1 and SLS4 are required
for recruitment of SR proteins
As a complement to the in vitro splicing inhibition study of
truncated NRSs described above, we attempted to identify
the nuclear proteins recruited by these NRSs mutant. To
this end, we used an RNP puriﬁcation approach that is
based on the fusion of MS2 sequences to the studied RNA
(29,30). The WT, 76, 22, 24, 26 and 28 NRS variant
RNAs, described above, were transcribed with three
binding sites for the MS2 coat protein fused at their
30-ends (Figure 4A). Each of these RNAs was bound to
a recombinant fusion protein containing the MS2 coat
protein RNA binding domain and the E. coli maltose
binding protein (MBP). The RNA–protein complexes
obtained were then incubated with a Hela cell nuclear
extract competent for in vitro splicing. The WT and
variant NRS RNPs formed were bound to amylose
beads, washed and eluted by addition of maltose, as
described in ‘Materials and Methods’ section.
Both the RNA and the protein composition of the
puriﬁed complexes were analysed. The presence of U1
snRNA and MS2 tagged RNAs in the puriﬁed complexes
was evidenced by northern blot analysis using speciﬁc
oligonucleotides (Supplementary Table S1), and
quantiﬁed as described in Figure 4. As expected, only
the deletion of the SLS4 sequence had a marked
negative effect on U1 snRNA association (Figure 4B
and C). Proteins present in the RNP complexes formed
with the WT NRS were subjected to SDS–PAGE, the
bands were cut and analysed by mass spectrometry. We
detected proteins already found to bind the entire NRS
element (ASF/SF2, hnRNP H) (19,21,45) among a large
number of other proteins. For a comparative analysis of
SR and hnRNP H and A1 proteins in RNP complexes
formed with the WT and variant NRSs, we turned to
the western blot approach using speciﬁc antibodies
(Figure 4D). As expected the SR proteins ASF/SF2,
9G8 and SC35 and the hnRNP H proteins were detected
in complexes formed with NRS WT. They were also
detected with NRSs 76, 22 and 28. In contrast, weak
amounts of ASF/SF2 and only traces of 9G8 and SC35
were detected in complexes formed with NRSs 24 and 26,
suggesting that both the SLS1 and SLS4 sequences are
required for efﬁcient binding of SR proteins. The strong
binding of hnRNP A1 to each of the truncated forms of
NRSs (Figure 4D) suggested a possible involvement of
this protein in regulation of NRS activity.
The SR protein 9G8 has a stimulatory effect on
NRS activity
Our observation of a strong binding of the SR protein
9G8 on NRS together with previous description of its as-
sociation with NRS (21) encouraged us to test for a
possible effect of this protein on NRS activity. First, we
used the in vitro splicing assay based on C2 derived
contructs. The C2-NRS WT RNA was spliced in HeLa
cell nuclear extract in the absence or the presence of
increasing amounts of recombinant 9G8 protein, which
had been produced in baculovirus. As illustrated in
Figure 5A and Supplementary Figure S5B, the NRS
3396 Nucleic Acids Research, 2011,Vol.39, No. 8inhibitory property was signiﬁcantly and reproducibly
increased by addition of the recombinant 9G8 protein,
whereas addition of BSA had no signiﬁcant effect. For
the C2-NRS WT RNA only 50% of the splicing activity
was detected upon addition of 270ng of 9G8.
To verify that 9G8 also stimulates the NRS inhibitory
property in cellulo, the C2, C2-NRS WT and C2-NRS Inv
DNA sequences from the in vitro constructs were inserted
within plasmid pGL3c, in such a way that they replaced
the luciferase gene. The resulting plasmids, pGL3-C2,
pGL3-C2 NRS WT or pGL3-C2 NRS Inv were co-
transfected in HeLa cells with either the empty plasmid
pXJ42 or plasmid pXJ42-9G8 expressing 9G8 protein and
48h after transfection, the amounts of spliced (Sp) and
spliced plus unspliced (Sp+UnSp) transcripts were
estimated by RT–PCR as described in Figure 6. The
over-expression of protein 9G8 by a factor of about
three reproducibly decreased splicing of the C2-NRS
WT RNA, but not of splicing of C2 and C2-NRS Inv
transcripts (Figure 6A and Supplementary Figure S5C).
Therefore, the stimulatory effect of 9G8 on the NRS
activity that we discovered by in vitro assays also exists
in cellulo.
To conﬁrm the existence of this stimulatory effect in
cellulo, we then diminished the level of 9G8 in HeLa
cells by using a si9G8 directed against the endogeneous
9G8 mRNA (si9G8) (40). As a control we used a siRNA
directed against the Renilla luciferase (siLuc) (41). Cells
were transfected twice with siRNAs and 48h later were
transfected by the C2, C2-NRS Inv or C2-NRS WT con-
structs for 24h. Two independent experiments were per-
formed and in our transfection conditions, the 9G8
concentration was decreased to a moderate extent
(factor of about 2) (Figure 6B and B1). In these condi-
tions, C2 RNA splicing was slightly decreased and we
reproducibly detected an increased splicing of C2-NRS
WT RNA (factor of about 2.5) while no increase was
detected in the control experiment performed with the
siLuc siRNA (Figure 6B, B2 and B3). Therefore, we
concluded that the strength of splicing regulatory
activity of RSV NRS depends upon the yield of expression
of protein 9G8.
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Figure 4. Only functional NRS variants bind SR proteins. (A) Schematic representation of NRS-MS2 and NRS-MS2 derived RNAs used in afﬁnity
selection experiments. The three binding sites for the MS2 coat protein (MS2 RNA) were fused to the 30-end of the NRS RNAs. Formation of RNP
complexes and their puriﬁcation is described in ‘Materials and Methods’ section. (B and C) Northern blot analysis of RNA from puriﬁed RNP
complexes, using 50-end-labelled U1 snRNA (O-6524) and MS2 RNA (O-6534) speciﬁc probes (Supplementary Table S1). The RNAs used to form
the RNP complexes are indicated above the lanes. M, is a mixture of MS2 and all NRS-MS2 RNAs used as size markers. NE corresponds to RNAs
extracted from cell nuclear extract without addition of exogeneous RNA. Intensities of the bands were quantiﬁed and the ratios of U1 snRNA versus
NRS-MS2 RNA are given in C. The U1 snRNA/NRS-MS2 RNA ratio obtained for the WT NRS RNA is taken as the 100% reference and ratios
obtained for the other NRS-MS2 RNA are given as a percentage of this reference. The mean values and standard deviations of two experiments are
shown. (D) Western blot analyses of SR and hnRNP proteins contained in the puriﬁed RNP complexes formed with the various NRS-MS2 RNAs.
Proteins extracted from equal amounts of puriﬁed complexes were analysed by western blot using antibodies speciﬁc for the SR and hnRNP proteins
indicated on the right side of the blot. The identity of the NRS-MS2 RNA used in the assay is given above the gel. Twomg of total proteins of HeLa
nuclear extract (NE) were loaded as a reference.
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inhibition by 9G8
Then, we used again in vitro splicing assays in order to
deﬁne which NRS regions are important to get the 9G8
stimulatory effect. Tests were performed three times on
each of the NRS 76, 22 and 28 variants (Figure 5B
and Supplementary Figure S5D). Strong increases of the
76 and 28 NRS inhibitory properties were reproducibly
detected in the presence of recombinant 9G8. In contrast,
addition of 9G8 protein did not stimulate the splicing in-
hibitory activity of the NRS 22 variant, showing that in
spite of the strong association of 9G8 with SLS1, the helix
H2 sequence which is missing in NRS 22 is required for
stimulation of the RSV NRS activity by 9G8. This sug-
gested a direct binding of protein 9G8 on sequences in
helix H2.
Therefore, for a better delineation of the 9G8 binding
sites on RSV NRS, we then performed footprinting assays
on RNP complexes formed by incubation of RSV WT
NRS transcripts with the recombinant 9G8 protein at
two distinct [9G8]/[RNA] ratios 25 and 50, respectively,
as described in ‘Materials and Methods’ section.
Formation of RNP complexes was veriﬁed by EMSA ex-
periments (data not shown). The patterns of T1 RNase
digestion of free and complexed RNA were compared
by primer extension analysis followed by gel electro-
phoresis. Examples of cDNA fractionation are shown in
Figure 7A, A1–A3. Neither SLS3 nor SLS4 are protected.
At the lowest [9G8]/[RNA] ratio, protections are mainly
detected in SLS1 and its bordering sequences and in the
purine rich large bulged loop in SLS2 (Figure 7B). Upon
increasing 9G8 concentration, protections in these regions
were reinforced and new protections are detected in helix
H2 (Figure 7B). Interestingly, these data are in agreement
with our ﬁnding of a requirement of the SLS1 sequence for
efﬁcient association of 9G8 to RSV NRS. They are also in
agreement with previous data suggesting that there are
9G8 protein binding sites in the RSV NRS segment ex-
tending from positions 740 to 798 (21). However, our data
AB
Figure 5. Protein 9G8 enhances NRS splicing inhibition properties in vitro.( A) WT NRS activity is strongly enhanced by 9G8 protein in vitro.C 2
(depicted in Figure 3A1), C2-NRS WT and C2-NRS Inv pre-mRNAs (depicted in Figure 3A2) were incubated for 2h in a 1:1 mixture of HeLa cell
cytoplasmic and nuclear extracts in the absence or the presence of puriﬁed recombinant human 9G8 protein (180 and 270ng) or BSA (500ng). RNAs
were subjected to RT–PCR analysis (in triplicate) as in Figure 3. One representative example of cDNA fractionation is shown (A1). Splicing
experiments were repeated three times using different batches of RNA. For each tested pre-mRNA, the Sp/Sp+UnSp ratio obtained in the
absence of 9G8 or BSA addition was taken as the 100% reference and the Sp/Sp+UnSp ratios obtained in the presence of 180 or 270ng of 9G8
or 500ng of BSA were expressed as a percentage of this reference. The data for the three splicing experiments are shown in Supplementary Figure
S5B. The mean values and the standard deviations of these experiments are given in A2. *P<0.05, **P<0.01, NS: not signiﬁcant. (B) 9G8 increases
the in vitro activity of the 76 and 28 variant NRSs but not of the 22 variant NRS. The C2-NRS Inv, C2-NRS 76, C2-NRS 22 and C2-NRS 28
pre-mRNAs were incubated in a 1:1 mixture of HeLa cell cytoplasmic and nuclear extract without (9G8
 ) or with (9G8
+) 270ng of 9G8 protein and
were subjected to RT–PCR analysis as described above. Three independent experiments were performed and a representative example of fraction-
ation of the RT–PCR products is shown in B1. The Sp/Sp+UnSp ratios were quantiﬁed as in Figure 3 and the Sp/Sp+UnSp ratio obtained in the
absence of 9G8 over-expression were taken as the 100% reference. The Sp/Sp+UnSp ratios obtained in the presence of 270ng of 9G8 were expressed
as a percentage of this reference. The percentages established for the three independent experiments are shown in Supplementary Figure S5, D. Their
mean values and standard deviations are given in B2. *P<0.05, **P<0.01, NS: not signiﬁcant.
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restricted to this segment.
DISCUSSION
Here, we describe the ﬁrst experimental analysis of the 2D
structure of the entire RSV NRS and based on a prote-
omic analysis, followed by in vitro splicing assays, we show
that the SR protein 9G8 stimulates the RSV NRS splicing
inhibition property.
Each of the NRS functional sequences belongs to a
deﬁned 2D structure motif and the possibility to form
these motifs is conserved in ASLVs
Retroviruses generally have highly structured genomic
RNAs in order to resist to digestion by RNases of the
AB
Figure 6. NRS activity in cellulo depends on the level of protein 9G8 expression. (A) Protein 9G8 also increases NRS activity in cellulo. DNAs of the
C2, C2-NRS WT and C2-NRS Inv constructs described in Figure 3A2 were cloned into plasmid pGL3c. HeLa cells were co-transfected with these
constructs and a vector expressing the 9G8 SR protein (9G8
+) or an empty vector as the control (9G8
 ); 48h after transfection, total cellular proteins
and RNAs were extracted as described in ‘Materials and Methods’ section and analysed by western blot after SDS–PAGE analysis (A1) and by RT–
PCR (A2 and A3), respectively. The presence of equal amounts of extracted proteins in each assay was controlled by western blots using b-tubulin
antibody and the level of 9G8 overexpression was evaluated by western blot using a speciﬁc 9G8 antibody. For RT–PCR analysis of the extracted
RNAs, the same primers as in Figure 3A2 were used, except that the RT primer was an oligo(dT) (Supplementary Table S1). Two independent
experiments were performed and a representative example of cDNA fractionation is shown in A2. For each of the tested constructs, the Sp/Sp+UnSp
ratios obtained in the absence of 9G8 overexpression was used as the 100% reference and the Sp/Sp+UnSp ratios obtained in the presence of 9G8
overexpression are expressed as a percentage of this reference. The percentages established for the two independent experiments are shown in
Supplementary Figure S5C. Their mean values and standard deviations are shown in A3. (B) NRS activity is strongly reduced upon decreasing
the cellular 9G8 protein concentration. HeLa cells were treated with siRNA targeting the 9G8 mRNA (si9G8) or with control siRNA (targeting
luciferase mRNA, siLuc) in conditions described in ‘Materials and Methods’ section. They were then transfected with plasmids pGL3-C2, pGL3-C2
NRS Inv or pGL3-C2 NRS WT. Total proteins and RNAs were extracted 24h after transfection and were analysed by western blot (B1) and RT–
PCR (B2 and B3), respectively, as described for the (A). Two independent experiments were performed and a representative exemple of cDNA
fractionation is shown in B2. RT–PCR were performed in triplicate and quantiﬁed, as described above. For each construct, the Sp/Sp+UnSp ratios
obtained for the control siLuc siRNA was taken as the 100% reference and the Sp/Sp+UnSp ratios obtained for the si9G8 siRNA are expressed as a
percentage of this reference. The mean values of the two independent experiments and their standard deviations are shown in B3.
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rule. It folds into a tight 2D structure. Other ASLV NRSs
can adopt this structure due to compensatory and
semi-compensatory base substitutions in the stems and
the location of several point mutations and insertion of
nucleotide stretches in single-stranded segments.
The structural motif established by NMR for a small
RSV NRS segment containing the pseudo 50-ss (23) is
included in the established structure. This motif corres-
ponds to the apical part of the SLS4 stem–loop structure.
Importantly, formation of this apical part of SLS4 was
previously shown to be needed for efﬁcient binding of
U1 snRNP to the pseudo 50-ss (23).
Our data change the conception of NRS architecture
which was based on a previous computer prediction
(13). We found that the ASF/SF2 binding region, which
is also shown here to bind protein 9G8, folds into a stem–
loop structure facing the stem–loop structure containing
the U1 and U11 binding sites. In the previous computer
model, these two sequences were in part base paired
AB
Figure 7. Enzymatic footprinting of 9G8 binding sites on RSV NRS RNA. (A1–A3) Primer extension analyses of RSV NRS cleaved by T1 RNase in
the absence or the presence of protein 9G8. RNA-protein complexes were formed at [9G8]/[RNA] molar ratios of 25 and 50, respectively. The
absence of protein addition is indicated by ( ). Enzymatic reactions were performed as described in ‘Materials and Methods’ section. Lanes U, G, C
and A correspond to the sequencing ladder and primers used for reverse transcription are indicated below each autoradiogram. Nucleotide num-
bering in the RSV NRS RNA and positions of the ASF/SF2 (19) binding site are indicated on the left side of the autoradiogram. Positions of helices
(H) and stem–loop structures (SLS) are shown on the right side of the autoradiograms. Cleavages by T1 RNase and protection generated by protein
9G8 are represented by arrows with two circles. Colours of the ﬁrst and second circles represent the level of protection obtained at the 25 and 50
[protein]/[RNA] molar ratios, respectively (white, black, blue and purple for none, low, medium and strong protection, respectively). (B) Schematic
representation of the protections generated by protein 9G8 is depicted on the RSV NRS RNA 2D structure using the same rules as in A. Primers are
indicated by blue arrows. The ASF/SF2 and snRNA U1 binding sites according to references (17,19) are highlighted in green and grey, respectively.
3400 Nucleic Acids Research, 2011,Vol.39, No. 8together (13). Absence of protection by protein 9G8 in the
SLS4 stem–loop, while sequences in SLS1 are protected, is
in agreement with the formation of two distinct structural
elements by these two NRS sequences. However, as the
sequences bordering the SLS1 and SLS4 stem–loops form
a large internal loop, one can imagine that the ﬂexibility of
this internal loop facilitates the establishment of inter-
actions between partners of SLS1 and SLS4: protein
ASF/SF2 and/or 9G8 bound to SLS1 and the U1
snRNP bound to SLS4. The nucleotide sequences of
these two stem–loop structures are highly conserved.
The possibility to form helix H1 was not taken into con-
sideration in the previous model. Based on the present
data, one of its functions may be to stabilize the NRS
structure. In addition, helix H1, whose primary sequence
is highly conserved, contains one of the G tracts (nucleo-
tides 935–942) which are needed to bind hnRNP H and
this binding is important for U11 snRNP association (46).
Conservation of this G tract in ASLVs is also in accord-
ance with the presence of similar G tracts downstream
from several of the minor 50-ss that bind U11 snRNP
(46). Sequences involved in helix H2 formation were pre-
viously proposed to bind SR proteins (47). Here, we show
that this helix is required for activation of NRS by protein
9G8 and delineated the H2 segment protected by this SR
protein.
Noticeably, the strong sequence conservations of SLS1,
SLS4, helix H1 and the bottom part of helix H2 can not be
simply explained by speciﬁc needs for coding capacity,
since all the NRS sequences code for a single polypeptide
(the Gag protein). Consequently, the strong conservations
of some parts of the NRS sequence and of its overall 2D
structure altogether likely reﬂect speciﬁc needs for NRS
activity.
SLS1, SLS2 linked together by helix H1 are sufﬁcient for
splicing inhibition
The HIV-1 derived construct that we designed for in vitro
and in cellulo assay of the NRS activity turned to be
efﬁcient. It shows that utilization of the pair of HIV-1
D1 and A2 sites can be efﬁciently down-regulated by the
heterologous NRS sequence. Accordingly, like the RSV
env and src 30-ss, the HIV-1 site A2 is poorly efﬁcient
due to the presence of: (i) suboptimal polypyrimidine
tract and branch site sequences and (ii) an ESSV inhibi-
tory element (31,43). By using the HIV-1-NRS heterol-
ogous construct, we conﬁrmed the requirement of
sequences contained in SLS1 for NRS activity and
showed that these sequences are as much important for
NRS activity as sequences in SLS4. This strongly suggest
that the previously identiﬁed ASF/SF2 binding sites in
SLS1 (19,20) and/or the presently identiﬁed 9G8 binding
sites in SLS1 is/are needed to get NRS activity. These data
are consistent with the absence of activity of the NRS
LR9 which is missing the sequence from position 735
to 776 (27).
The NRS 76 variant was previously deﬁned as the
minimal functional NRS element (13). Interestingly,
although shorter in length than NRS 76, variant NRS
28, designed on the basis of the RNA 2D structure,
inhibited in vitro splicing as efﬁciently as the NRS 76.
Most importantly, we could design a very short NRS
variant (NRS 22), which is still able to inhibit splicing
in vitro. This is the ﬁrst observation of the activity of a
very small NRS variant, which only contains SLS1 linked
to SLS4 by helix H1.
Increased protein 9G8 concentration reinforces the NRS
inhibitory property
Whereas the SR protein 9G8 was previously shown to
bind NRS, its activity on this element had never been
tested directly. Here, by in vitro and in cellulo splicing
assays, we show the dependence of the NRS activity on
the 9G8 protein concentration. The effect on NRS activity
observed upon addition of 9G8 protein in nuclear extract
was almost opposite to that observed upon decreasing the
9G8 concentration by siRNAs in cellulo. Importantly also,
addition of extra 9G8 protein in nuclear extract increased
the NRS WT, 76 and 28 activity, but had no effect on
the NRS 22 inhibition property, in spite of the presence
of 9G8 binding sites in SLS1. We propose the following
interpretation of our splicing data. First, by binding to
SLS1, protein 9G8 may have in combination with ASF/
SF2 a positive basic effect on NRS activity. Secondly, at
higher concentration, by binding to sequences in helix H2
which are present in NRS 76 and 28 but are missing in
NRS 22, protein 9G8 may have a supplementary stimula-
tory effect on NRS activity.
Altogether, our data bring strong support to the impli-
cation of protein 9G8 in modulation of NRS activity.
Obviously, these data were obtained by using human
nuclear extracts and recombinant human SR proteins,
which are more easily available than splicing competent
avian nuclear extracts. However, based on the strong
sequence conservation of SR proteins and components
of the splicing machinery in mammalian and avian organ-
isms, we propose that activation of NRS by the 9G8 avian
counterpart protein also takes place in avian cells.
Deletions of SLS1 or SLS4 both have a negative effect on
SR binding to NRS in nuclear extract
Our adaptation of the MS2 based RNP puriﬁcation
method to the puriﬁcation of RNP complexes formed by
WT or variant NRSs upon incubation in nuclear extract
led to an unexpected result: binding of SR proteins to
NRS is found to depend on both SLS1 and SLS4, while
binding of U1 snRNP is strictly dependent on the presence
of SLS4. The dependence of the binding of the SR
proteins ASF/SF2 on the presence of SLS1 is in agreement
with previous data showing its direct binding to a segment
overlapping SLS1 (19,20). Finding of a requirement of
SLS1 for recruitment of proteins 9G8 is in accord with
our 9G8 footprinting assays (Figure 7A and B).
Our ﬁnding of a strong negative effect of SLS4 deletion
on SR protein binding is unexpected. Firstly, because we
found no signiﬁcant protection of SLS4 in RNP
complexes formed with protein 9G8 (Figure 7A and B),
secondly because the NRS segment extending from
position 715 to 748 binds alone the recombinant ASF/
SF2 protein (19). One possible explanation is that, in
Nucleic Acids Research,2011, Vol.39, No. 8 3401nuclear extracts containing a high level of protein hnRNP
A1, binding of the U1 snRNP or other splicing factors on
SLS4 may help SR protein to compete with hnRNP A1
and to bind to SLS1. Accordingly, we detected a strong
binding of hnRNP A1 on all the truncated NRSs that
were tested, which was conﬁrmed by footprinting assays
(data not shown).
One model to explain the overall data presented in this
paper is that the role of SR proteins in NRS activity is
probably not to reinforce U1 snRNP binding on NRS but
to couple the NRS pseudo 50-ss to the RSV 30-ss, which is
needed for splicing inhibition. SR proteins and hnRNP A1
likely compete for binding to NRS and in future studies
the possible role of hnRNP A1 will have to be
investigated.
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